New hope for vulnerable patients: can stronger antiviral cocktails beat COVID-19?

NCT ID NCT07406217

First seen Feb 16, 2026 · Last updated May 15, 2026 · Updated 8 times

Summary

This study looks at whether using two antiviral drugs together (remdesivir plus nirmatrelvir/r) works better than one drug alone for treating COVID-19 in people with weakened immune systems. It also tests if taking the medication for 10 days instead of 5 helps clear the virus faster. About 256 adults with mild to moderate COVID-19 and immune deficiencies will take part. The goal is to find safer, more effective ways to manage COVID-19 in this high-risk group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID - 19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Basel University Hospital

    RECRUITING

    Basel, Basel, 4031, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHUV

    RECRUITING

    Lausanne, Canton of Vaud, 10-549, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hôpitaux Universitaires de Genève

    RECRUITING

    Geneva, Canton of Geneva, 1205, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Zurich

    RECRUITING

    Zurich, Canton of Zurich, 8091, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.